



National
Germ Cell
Group

Welcome to Manchester Virtual Conference

Online Monday 22nd February 2021

for two weeks, concluding with

Live Event Monday 8th March 2021

The Christie Education Centre



www.nationalgermcellgroup.org.uk

Welcome to the second National Germ Cell Group Conference 2021



Sue Brand (NGCG Chair and Event organiser)

Well, it appears we actually got there! The Covid-19 pandemic has certainly proved to be a game changer and we have been absolutely overwhelmed that during these most testing of times, our conference has been met with enthusiasm.

For those who have not attended in the past, the group was originally formed by specialist nurses in 2012 and changed its remit in 2017. In 2018, the first multi-disciplinary conference took place in Bristol.

Some of the original team continue to steer the group including myself, Wendy Ansell and Catherine Pettersen. Sadly, Paul Hutton stepped down in 2020 due to work commitments but we have been joined by Gemma Crane CNS from UCARE, Michelle Greenwood CNS Barts and Vince Wolverson CEO of It's on the Ball Charity. We have been lucky to have the continued support of Dr Jonathan Shamash, however Professor Andrew Protheroe, Dr Sara Stoneham and Prof Jonathan Joffe decided to step down. We are currently looking for keen oncologists to join the team.

I would like to thank Dr Mike Leahy and the steering group who have helped enormously with the programme and organisation of this year's conference which technically is still coming from Manchester. I retired from nursing as a Germ Cell CNS in 2018 and now feel it is time to hand over the role of chair and who better than to Michelle Greenwood. Michelle will continue the enthusiasm of the group and is a great advocate of patient support and involvement. I wish her well however I will be there to support and organise the next event.

Steering Group



Wendy Ansell; Catherine Pettersen; Gemma Crane; Vince Wolverson; Michelle Greenwood

Dr Mike Leahy


Consultant Medical Oncologist, The Christie Hospital NHS FT, Manchester

Welcome to the delayed 2020 conference of the National Germ Cell Group.

How I wish I was able to welcome you to Manchester in person, to see and meet and talk to you in person: over a coffee, at dinner, in front of a poster. However, our on-line conference is salvaging the most important elements of our conference and, for some people, of course, will actually be easier, more convenient and better. The importance of the NGCG is about connecting.

We are a tiny community of professionals and advocates (and patients) in the wider community of cancer and making contact with each other is therefore more important than in other tumour types. We designed the conference not only to be able to share research results and opinion to help us keep up to date but also as an opportunity to showcase our services to each other and to aid networking. We are one of the last tumour specific groups to organise in this way and we all owe a debt of thanks to the core group of clinical nurse specialists, led by Sue Brand, who were the catalysts.

Sue is stepping back this year from running the Group and handing over to Michelle Greenwood and I have every hope that the new Spring that comes after this Covid Winter will see the germination of a new and enthusiastic steering group and regular conferences over the years to come.



Michelle Greenwood

Macmillan Uro-Oncology Clinical Nurse Specialist; Lead Teenage and Young Adults Nurse St Bartholomew's Hospital London

Michelle graduated from City University in 2008 and worked on a solid oncology ward at Barts until 2010 moving into district nursing for 6 months. She returned to Barts to undertake Research Nursing in Urological Cancers (renal and prostate studies) and then became Ocular Melanoma CNS (2014) before returning as the CNS in Uro-oncology in 2015 (current post). Special Interests: Testicular & renal cancer (bladder and prostate cancer also covered), health promotion and cancer survivorship, service development, Teenage and Young Adults (TYA) with cancer. Within her current role is an attached lead cancer nurse for Teenagers & Young Adults with cancer (TYA) at Barts as the germ cell practice incorporates those in the 19 - 25year age group who may have additional care needs. Whilst in her current post she has set up a testis cancer support group and is a member of the organising committee for this year's NGCG conference.



VIRTUAL CONFERENCE - LIVE EVENT MONDAY 8TH MARCH 2021

VIRTUAL CONFERENCE - LIVE EVENT MONDAY 8TH MARCH 2021	
1000: WELCOME & INTRODUCTION TO THE LIVE EVENT 2021	Dr Mike Leahy
1005: POSTERS AND HOW TO VOTE	Catherine Pettersen
A REVIEW OF THE PRE-RECORDED PRESENTATIONS AND ONLINE QUESTIONS	
1010: PRESENTATIONS 1-4 NEW PERSPECTIVES OF THE ROLE OF LOCAL THERAPY IN METASTATIC SEMINOMA - Professor Robert Huddart FEMALE GERM CELL CANCER - Dr Michelle Lockley TERATOMA DIFFERENTIATED AND SOMATIC MALIGNANT TRANSFORMATION - Prof Daniel Berney POTENTIAL CLINICAL UTILITY OF CIRCULATING MICRORNAS FOR TESTICULAR GERM CELL MALIGNANCY - Dr Matt Murray	Dr Mike Leahy
1020: PRESENTATIONS 5-8 100 000 GENOMES AND TESTICULAR CANCER (THIS SESSION IS TO BE CONFIRMED)- TBC GERMLINE GENOMIC ARCHITECTURE OF TESTICULAR GERM CELL TUMOURS - Dr Chey Loveday NHS SCOTLAND QUALITY PERFORMANCE INDICATORS (QPIS) FOR TESTIS CANCER - Dr Jeff White and Dr Mark Baxter SOCIAL MEDIA, WHY ARE HEALTH CARE PROFESSIONALS SO SCARED? - Shievon Smith	Dr Jeff White
1040: PRESENTATIONS 9-12 ADAPT PROJECT - Prof John Radford BLEOMYCIN- FRIEND OR FOE? - Prof Colm Leonard DEALING WITH DIAGNOSTIC UNCERTAINTY: MICROLITHIASIS AND SMALL TESTICULAR LESIONS - Prof Noel Clarke REVIEW OF RECENT, ONGOING AND UPCOMING TRIALS: TRYMS, TRISST, TIGER, P3BEP, AGCT 1531; BLEO LD - Prof Dan Stark REVIEW OF RECENT KEY PUBLICATIONS IN FIELD OF GERM CELL / TESTIS CANCER - Dr Jonathan Shamash	Dr Jonathan Shamash
1050: USING A WHATSAPP GROUP TO GUIDE CLINICAL PRACTICE DURING THE COVID-19 PANDEMIC	Professor Dan Stark
1100: HAS THERE BEEN AN INCREASE IN SIZE OF TESTICULAR MASSES DURING THE COVID-19 PANDEMIC?	Dr Jonathan Shamash
1110: CNS PERSPECTIVE OF CARING DURING THE COVID-19 PANDEMIC	Michelle Greenwood
1120: MDT's FEEDBACK OF THE OUTCOMES FROM THE COVID-19 PANDEMIC	Dr Mike Leahy
1200: CHARITY AND PATIENT GROUP FEEDBACK	Vince Wolverson & Gemma Crane
1230: VOTE FOR POSTERS	ALL
1235: NATIONAL GERM CELL GROUP - Sue Brand (Chair): Update on the NGCG past and future, thank the team and invite delegates to join the Steering Group. Conference 2023 and formally handover the role of Chair to Michelle Greenwood.	Sue Brand, Wendy Ansell, Cath Pettersen, Gemma Crane, Vince Wolverson & Michelle Greenwood
1250: POSTER PRIZES AND PRESENTATIONS	Cath Pettersen
1255: CLOSING NOTES AND EVALUATIONS	Dr Mike Leahy

The National Germ Cell Group Virtual Conference 2021
has been supported by





**Dr Michael Leahy Consultant Medical Oncologist
The Christie Hospital NHS FT, Manchester**

Michael Leahy was inducted into the family of medical oncology by Professor Tim Oliver, completed a PhD with him in testicular cancer and has subsequently practiced in the civilised North including Leeds and Manchester. He is daily amazed by the ability of chemotherapy to cure patients with widely metastatic cancer and confounded when it fails. He has a particular research and service development interest in rare cancers including testis, sarcoma and cancer in the TYA age group.

**Professor Robert Huddart
Institute of Cancer Research and Royal Marsden Hospital**



Robert Huddart's major research interests are in bladder and testicular cancer. In regard to testicular cancer his major interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorship issues and the genetics of testicular cancer. He has served as Chair of the National Cancer Research Institute Testis CSG, had been chief investigator and co-investigator of a number of major UK/international protocols.



**Dr Michelle Lockley
Consultant in Medical Oncologist University College Hospital & Deputy Lead for the Centre for Cancer Cell and Molecular Biology and Reader in Medical Oncology.**

Dr Lockley specialises in the treatment of ovarian cancer. She completed her PhD in oncolytic viral therapies in ovarian cancer at the Barts Cancer Institute (BCI), Queen Mary University of London and subsequently held a NIHR Clinical Lectureship at the University of Cambridge. Dr Lockley has held both a Clinician Scientist Fellowship and an Advanced Clinician Scientist Fellowship from Cancer Research UK. She leads a laboratory research team at BCI where she is Deputy Lead for the Centre for Cancer Cell and Molecular Biology and Reader in Medical Oncology.

She practices clinically at University College London Hospital. Dr Lockley's research aims to discover new systemic treatments for ovarian cancer. Her lab is particularly interested in novel viral and immunotherapies as well as strategies to tackle treatment resistance including drug re-purposing and adaptive therapy. She has a clinical research interest in rare gynaecological cancers, particularly ovarian germ cell tumours and is a member of MaGIC, the malignant germ cell tumour international consortium. To support research into gynaecological malignancies, she set up and continues to lead the Barts/UCLH Gynae Tissue Bank, a repository of tissues and clinical data that are kindly donated by her patients.

**Wendy Ansell
Retired Macmillan Urology Nurse Specialist**



Wendy was the first Macmillan Urology Nurse Specialist in the UK and remained in that role in Medical Oncology at Barts for 20 years until retirement from clinical work in 2017. Since qualifying at Barts in the 1970's, Wendy spent the greater part of her nursing career in cancer nursing in both hospitals and hospices. The particular interest in uro-oncology started when she was a Ward Sister at the Royal Marsden in the 1970's and was privileged to be looking after young men with metastatic testicular cancer when cisplatin came into clinical use and revolutionised the outcomes of treatment. As Macmillan CNS, a large part of the role was supporting men with testicular cancer at all stages of their disease and support after treatment has finished. Nationally, Wendy has fulfilled diverse roles including being the founder chair of the BAUN Section of Oncology, a member of the steering group for the UK prostate link website, an early reviewer for testis cancer Peer Review measures & reviewing patient information for a number of national charities. She is currently a Steering Group member for the National Germ Cell Group.



**Catherine Pettersen:
Macmillan Urology Clinical Nurse Specialist, The Christie NHS Foundation Trust**

Catherine qualified as SRN in 1983, worked on Neurosurgical ward for 2 years and then moved into Oncology, and has worked in this area for 30 years. Initially working on the surgical oncology ward at The Christie, then as a Nurse Practitioner in the Acute Oncology Service. She then moved to a local DGH as a Macmillan Breast Care CNS in 2003, returning to the Christie in 2007 in her present role. At that time she established the CNS service for testicular cancer patients at the Christie NHS foundation Trust which is a Supra Regional centre for testicular cancer. She works with both oncology and surgical teams, which is advantageous when patients require multi-modality treatment. Catherine has done advanced clinical skills training and reviews testicular cancer patients within the consultant testicular clinics and runs nurse led prostate cancer clinics in the community. She is a steering group member of the National Germ Cell Group



Prof Dan Berney
Consultant Urological and Endocrine Pathologist
Barts Health



Dan Berney is currently working at Barts. He has been Secretary of the International Society of Urological Pathologists, Chairman of the British Society of Urological Pathologists and is currently Editor in Chief of the journal Histopathology. He has over 200 papers and was one of the architects of the revised WHO classification of testicular tumours in 2015.



Dr Matt Murray University Lecturer and Honorary Consultant Paediatric Oncologist
University of Cambridge and Department of Paediatric Haematology and Oncology Cambridge
University Hospitals NHS FT

Matt is at Cambridge University Hospitals NHS FT monitoring and detection of relapse in this disease. Biology Co-Lead and Executive Committee Member of MaGIC (Malignant GCT International Collaborative) Member of NCRI TYA and Testis Cancer Clinical Studies Group. Matthew Murray has a particular interest in the clinical and molecular aspects of germ cell tumours (GCTs), and was the first to demonstrate the potential utility of specific circulating microRNAs for diagnosis, disease.

Dr Jeff White

Glasgow Consultant Medical Oncologist & Honorary Clinical Senior Lecturer Beatson West of
Scotland Cancer Centre, Glasgow and University of Glasgow



Jeff White has been a consultant medical oncologist at the Beatson West of Scotland Cancer Centre since 2004, his tumour types are germ cell cancer and sarcoma, leading to an interest in TYA oncology.

He particularly enjoys working in the multi professional teams associated with the management of these cancers. He is the principal investigator on a number of multi institutional phase 2&3 studies in these areas.



Shievon Smith
Uro-Oncology Clinical Nurse Specialist. St Bartholomew's Hospital, London

Shievon Smith has had a professional career in Nursing for 18 years; DipHE Nursing. Clinical background A&E. Changed to Urology then uro-oncology in a CNS training post at Broomfield Hospital. Completed Cancer BSc at the Royal Marsden. Currently working at St Barts as a CNS for Dr Shamash, Dr Alifrangis and Prof Powles. Special interests Bladder cancer and patient survivorship.

Prof John Radford

Professor of Medical Oncology Division of Cancer Sciences
University of Manchester and The Christie Hospital NHS FT



John Radford has had a career long interest in Hodgkin and non-Hodgkin lymphoma. He currently leads the NIHR Manchester Patient Safety Translational Research Centre's theme on the oncology tertiary care/primary care interface. John has a major interest in reducing late treatment toxicity especially in second cancers. He chairs the Centre for Living Beyond Cancer Science steering committee and is also leading several digital health projects. At the Christie Hospital John leads a busy clinical practice in lymphoma and has

been Director of Research since 2007.



Mr Aziz Gulamhusein
Consultant Urological Surgeon The Christie NHS Foundation Trust and Salford Royal Hospitals
Manchester

Mr Gulamhusein is a Consultant Urological Surgeon based at The Christie NHS Foundation Trust with a specialist interest in testicular cancer, kidney cancer and sarcoma for which he performs complex open and robotic retroperitoneal surgery. He holds an honorary contract at The Royal Marsden Hospital in London and visits regularly for joint operations with the testicular cancer team. Mr Gulamhusein graduated from Sheffield Medical School in 2008 and proceeded to complete his basic surgical training and urological training within the South Yorkshire. He subsequently undertook a prestigious Royal College of Surgeons (RCS) robotic kidney surgery fellowship at the Royal Free Hospital in London, the highest volume kidney surgery centre in Europe with >400 cases a year. Prior to undertaking his fellowship in London, he was awarded an RCS grant to visit a ERUS robotic host centre in Aalborg, Denmark. He has a keen interest in medical education and was a previous lead for the urology module at the Sheffield Medical School. He has completed a Postgraduate Certificate in Medical Education and is on the faculty for various courses and educational programmes. His research interests include the use of novel technology to improve surgical outcomes as well as enhanced recovery from surgery.



Prof Colm Leonard
Consultant Clinical Adviser Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence

Colm Leonard is a Thoracic Physician with an interest in lung transplantation.



Prof Dan Stark
Professor of Teenage and Young Adult Cancer Research Consultant in Medical
Oncology. Department of Oncology, Leeds Institute of Oncology, St James's Hospital, Leeds.

Dan Stark is a consultant in medical oncology who has led the regional germ cell practice across our network of around 5 million people from 2006 to 2020. He is the current chair of the NCRI Teenage and Young Adult and Germ Cell tumour Research group. He has a research portfolio including models of care for TYA, service innovation for germ cell tumours, and basic biology of germ cell tumours.

Dr Jonathan Shamash
Consultant Medical Oncologist / Honorary Senior Lecturer
Department of Medical Oncology St Bartholomew's Hospital London

Jonathan Shamash is a medical oncologist specializing in management of urological cancers in particular germ cell tumours. He is the Chair of the Germ Cell subgroup of the NCRI TYA/GCT National Clinical Study Group and has been responsible for developing clinical studies in testicular cancer. He is Chair of the Anglian Germ Cell Network. The data collected by this group has been used in large scale collaborations. He is interested in the de-escalation of therapy for metastatic germ cell tumours – with the use of carboplatin monotherapy in metastatic seminoma and the development of non cisplatin based combination chemotherapy in the management of relapsed germ cell tumours.



Dr Chey Loveday
Higher Scientific Officer, Institute of Cancer Research (ICR), London, UK

Chey undertook his PhD in cancer genetics at the ICR between 2008–2012. He has a combined 10 years plus experience within the division of Genetics and Epidemiology at the ICR, straddling both wet lab and dry lab activities. His work, as part of a team, has led to the identification and characterisation of multiple novel and known genetic determinants of testicular, breast and ovarian cancer, including both common and rare susceptibility alleles. His current research aims include further delineation of the germline genomic architecture of susceptibility to various cancers through large-scale GWAS and whole exome sequencing studies.

Vince Wolverson
CEO It's on the Ball Charity

Born in Rotherham, South Yorkshire. Served for 30 years in the Royal Air Force as an Aircraft Weapons Engineer. Whilst serving at RAF Marham was diagnosed in 1989 with Testicular Cancer (malignant Teratoma) and, following an orchidectomy (removal of the affected testicle) at the RAF Hospital at Ely, underwent a 3 month course of chemotherapy at RAFH Halton as the cancer had spread to the abdomen (both these establishments closed following various defence cuts). On retirement from the RAF in 2006 became a Lift/Crane Engineer Surveyor for Zurich Insurance. In 2009 detected a lump in the remaining testicle which proved to be stage one seminoma testicular cancer, after the testicle had been removed, a single dose of chemotherapy was given to help prevent the cancer from spreading. This treatment was carried out at the Norfolk & Norwich University Hospital. In January 2019 I took early retirement to take up the position of CEO of the charity on a part-time paid basis. My message is not only to all the guys to check themselves regularly, but also to all the 'one-ballers' out there to continue to do so – lightning can, and does, strike twice!



Gemma Crane
Lead Community Nurse UCARE

Gemma qualified from Nottingham with a Masters in Nursing and initially worked in London, before moving to Oxford as a cancer nurse specialist working in Uro-Oncology. During this time she helped to establish and develop the service concentrating on the holistic care and management of patients. She was involved in the initial set up of the TYA service as well as a role within the cancer network and was a member of the National Cancer Research Institute Testicular Cancer Clinical Studies Group. Gemma also has worked as a Macmillan Development Manager in Hertfordshire and Bedfordshire before moving into the private sector on a nurse consultancy basis both developing services and raising standards. She works part time for UCARE as the Lead Community Nurse and has been invaluable on the steering group being a representative of the TCN.



Online Sessions, Posters and Charities

Our YouTube Channel is here: https://www.youtube.com/channel/UChE_YiwjbHAUnq1L6rBRmUw

For all registered delegates, the online sessions will be available for 2 weeks from Monday 22nd February 2021. This is a secure channel and the link will be sent to you via email

The Speakers will log in during those 2 weeks and answer any questions you may have.

There is a small opportunity for more discussion on Monday 8th March at the Live Event.

Posters and Charity information are available on our website:

www.nationalgermcellgroup.org.uk

Live Event - Monday 8th March 2021 (10am - 1pm)

The live event will take place through The Christie Education Centre.

Details of how to join the event will be emailed to you directly from The Christie Education Centre.

Continuing Professional Development Credits

This conference has applied for 5 CPD credits and this will be noted on your certificate.

Your certificate and delegation list will be emailed to you after we have received your evaluation form for the conference.

Delegation list

We will be distributing a full list of delegates who were happy to be added, after the conference.

Evaluations

This will come from the education centre and they will send the results to us for consideration. Once we have received your evaluation form we will send you your certificate.

VIRTUAL CONFERENCE 2021 PROGRAMME

1. NEW PERSPECTIVES OF THE ROLE OF LOCAL THERAPY IN METASTATIC SEMINOMA	Prof Rob Huddart
2. FEMALE GERM CELL CANCER	Dr Michelle Lockley
3. TERATOMA DIFFERENTIATED AND SOMATIC MALIGNANT TRANSFORMATION	Prof Dan Berney
4. POTENTIAL CLINICAL UTILITY OF CIRCULATING MICRORNAs FOR TESTICULAR GERM CELL MALIGNANCY	Dr Matt Murray
5. GERMLINE GENOMIC ARCHITECTURE OF TESTICULAR GERM CELL TUMOURS	Dr Chey Loveday
6. NHS SCOTLAND QUALITY PERFORMANCE INDICATORS (OPIS) FOR TESTIS CANCER	Dr Jeff White and Dr Mark Baxter
7. SOCIAL MEDIA, WHY ARE HEALTH CARE PROFESSIONALS SO SCARED?	Shievon Smith
8. ADAPT PROJECT	Prof John Radford
9. BLEOMYCIN- FRIEND OR FOE?	Prof Colm Leonard
10. DEALING WITH DIAGNOSTIC UNCERTAINTY: MICROLITHIASIS AND SMALL TESTICULAR LESIONS	Mr Aziz Gulamhusein
11. REVIEW OF RECENT, ONGOING AND UPCOMING TRIALS: TRYMS, TRISST, TIGER, UK3PEP, AGCT 1531; BLEO LD	Prof Dan Stark & Chief Investigators
12. REVIEW OF RECENT KEY PUBLICATIONS IN FIELD OF GERM CELL / TESTIS CANCER	Dr Jonathan Shamash

POSTERS ENTRIES

1. Perioperative safety and short-term oncological outcomes of minimally invasive retroperitoneal lymph node dissection
2. A risk benefit analysis of prophylactic anticoagulation for patients with metastatic germ cell tumours undergoing first-line chemotherapy
3. Escalated Etoposide/Cisplatin in Malignant Germ Cell Tumours
4. Adaptations to the Germ Cell Tumour (GCT) Service during the Covid19 pandemic
5. From inequality to equity. How far have we come? How far do we have to go?
6. Primary Somatic Transformation of Testicular Germ Cell Tumors. Pathology and Outcome.
7. An analysis of incidence, histology, stage and prognostic group in male germ cell tumours in the North East of Scotland
8. Germ cell experience of haematopoietic autologous stem cell transplants.
9. Patient and Staff Experience of Testicular Cancer Support Group at St Bartholomew's Hospital
10. Patient perceptions of replacing CT scan based follow-up with a blood test: acceptability of circulating microRNAs for testicular germ cell malignancy relapse detection
11. Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
12. Patient Experience of Carboplatin AUC10 compared with BEP at St Bartholomew's Hospital
13. Testicular cancer prosthesis: understanding current practices of healthcare professionals and patients' experiences and views
14. Preparing teenagers and young adults for life beyond cancer
15. A review of 82 consecutive patients diagnosed with Testicular Sex Cord Stromal Tumours
16. Management of Stage I Seminoma in a Patient with Cystic Fibrosis (CF)
17. Testicular Cancer Patients' Awareness of Charity Organisations in a Tertiary Cancer Centre
18. Young adults with intracranial germ cell tumours presenting as an emergency: a retrospective study
19. Interesting clinical scenario in patient presenting with intraperitoneal bleed at diagnosis with metastatic testicular cancer



Wendy gough
cancer
awareness
foundation.



ORCHID
FIGHTING MALE CANCER



March 2021

All rights reserved

www.nationalgermcellgroup.org.uk
admin@nationalgermcellgroup.org.uk
@NGermCellG